Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immune Response of Immunose FLU in Older Adults
NCT03437304Phase 2Completed
- Sponsor
- Eurocine Vaccines AB
- Start
- Feb 2018
- Primary completion
- Jun 2018
- Modality
- Prophylactic Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Immunose FLU in influenza (7 arms), sponsored by Eurocine Vaccines AB. Primary endpoint: Safety of Immunose FLU based on Endocine and quadrivalent influenza antigens at Day 201. Started Feb 2018; status: completed.
02
Drugs
Immunose FLU
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03437304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03437304.